ChromoCure Enters Into Technology Exchange and Collaboration Agreement With Genome Research Group to Acquire Therapeutic Modelin
30 Marzo 2010 - 3:00PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure, announced today
the signing of a Joint Venture and Technology Sharing Agreement
with Genome Research Group (GRG). Under the Agreement ChromoCure
will have access to GRG's proprietary advanced therapeutic modeling
protocols and algorithms utilizing hypothermic modulation and
resonance for the non-toxic and non-invasive treatment of cancer.
GRG will have complete access to the Company's chromosomal
scanner technology including a complex and innovative series of
systems, processes, cell preparation techniques and diagnostic
algorithms. GRG will use the company's technology for on-demand,
real-time cancer progression analysis to monitor and determine
treatment efficacy. GRG's advanced Therapeutic Modeling Protocols,
together with ChromoCure's landmark Chromosomal Scanning
Technology, further strengthens the Company's leadership in Cancer
Detection, Therapy and Cure, and puts new impetus to its
groundbreaking Project Boveri: Finding the Cure.
The Agreement will provide ChromoCure access to the
following:
- hypothermic modulation and resonance protocols
- systems engineering specifications for human and animal
applications
- remission monitoring protocols, procedures, and remission
predictors
- tumor therapeutic growth and remission projection models
- remission estimation and projection models
- cancer stage analysis measurement and prediction model
- animal tumor eradication models and remission protocol
models
- animal metastasis prediction technology and equations
- metastasis remission protocol and projection analysis
- leukemia progression prediction and measurement, metastasis
reversion procedures
The Agreement is a further step in the Company's transition to a
focused Cancer Therapy and Cure Research & Development
organization. The Company recently announced its accelerated
Therapy and Cure initiatives through the launch of Project Boveri:
Find the Cure, properly reflecting its pioneering role in cancer
detection, therapy and cure and its increased research programs and
collaborations.
The Company's proprietary Chromosomal Scanner systems have
proven accurate and efficient in the measurement of the unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has been proven
to have an effective accuracy of 100% for all cancers at all
stages. This is superior to other detection approaches presently
relied upon by pathologists, including genetic or protein biomarker
detection.
ChromoCure's systems measure aneuploidy as the sole means of
detecting cancer presence and measuring cancer progression. The
system has a 100% effective accuracy rate. The Company recently
published its collaborative clinical testing with a major cancer
clinic.
About ChromoCure ChromoCure develops and provides proprietary
cancer detection systems and related therapeutic technologies. The
Company's proprietary CS200 Chromosomal Scanner has been proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has an effective
accuracy of 100% for all cancers at all stages. The Company
believes its technology will become the worldwide gold standard for
cancer detection, progression measurement, and research for both
therapy and cure. The Company also applies its technology and
knowledge to cancer cure and therapeutics research.
Safe-Harbor Statement This release contains statements or
projections regarding future performance that is forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
projected as a result of certain risks and uncertainties. The
company's filings contain various RISK FACTORS (and are
incorporated herein by reference) and should be read before any
investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Grafico Azioni Chromocure (CE) (USOTC:KKUR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Chromocure (CE) (USOTC:KKUR)
Storico
Da Set 2023 a Set 2024